One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma

Journal of Nippon Medical School

Volumn 77, Issue 1, 2010, Pages 21-28

  Nonaka, Manabu ^a,b   Sakanushi, Atsuko ^a   Kusama, Kaoru ^a,b   Ogihara, Nozomu ^a,b   Yagi, Toshiaki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

Author keywords

Anti leukotriene; Asthma; Chronic rhinosinusitis; Eosinophils; Intranasal corticosteroid

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; MONTELUKAST; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC DISEASE; CHRONIC RHINOSINUSITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOSCOPY; EOSINOPHIL COUNT; ETHMOID SINUS; FEMALE; FRONTAL SINUS; HUMAN; IMMUNOMODULATION; MALE; MAXILLARY SINUS; NOSE POLYP; ONSET AGE; PATIENT COMPLIANCE; PERIPHERAL CIRCULATION; RHINOSINUSITIS; SCORING SYSTEM; SPHENOID SINUS; TREATMENT DURATION;

ACETATES; ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; ADULT; AGED; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ASTHMA; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; NASAL POLYPS; QUINOLINES; RHINITIS, ALLERGIC, PERENNIAL; SINUSITIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 76249088750     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.77.21     Document Type: Article

References (20)

1. Nguyen LH, Fakhri S, Frenkiel S, Hamid QA: Molecular immunology and immunotherapy for chronic sinusitis. Curr Allergy Asthma Rep 2003; 3: 505-512.
2. Leynaert B, Neukirch F, Demoly P, Bousquet J: Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106: S201-205.
3. Bresciani M, Paradis L, Des Roches A, et al: Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001; 107: 73-80.
4. ten Brinke A, Grootendorst DC, Schmidt JT, et al: Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002; 109: 621-626.
5. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ: Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107: 469-476.
6. Steinke JW, Bradley D, Arango P, et al.: Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis:importance to eosinophilia and asthma. J Allergy Clin Immunol 2003; 111: 342-349.
7. Lildholdt T, Rundcrantz H, Lindqvist N: Efficacy of topical corticosteroid powder for nasal polyps:a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol Allied Sci 1995; 20: 26-30.
8. van Camp C, Clement PA: Results of oral steroid treatment in nasal polyposis. Rhinology 1994; 32: 5-9.
9. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH: Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347: 1493-1499.
10. Ragab S, Parikh A, Darby YC, Scadding GK: An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001; 31: 1385-1391.
11. Lund VJ, Mackay IS: Staging in rhinosinusitus. Rhinology 1993; 31: 183-184.
12. Tuncer U, Soylu L, Aydogan B, Karakus F, Akcali C: The effectiveness of steroid treatment in nasal polyposis. Auris Nasus Larynx 2003; 30: 263-268.
13. Bonfils P, Nores JM, Halimi P, Avan P: Corticosteroid treatment in nasal polyposis with a three-year follow-up period. Laryngoscope 2003; 113: 683-687.
14. Hamilos DL, Thawley SE, Kramper MA, Kamil A, Hamid QA: Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease. J Allergy Clin Immunol 1999; 103: 79-87.
15. Adachi T, Motojima S, Hirata A, et al: Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J Allergy Clin Immunol 1996; 98: S207-215.
16. Gibson PG, Dolovich J, Girgis-Gabardo A, et al.: The inflammatory response in asthma exacerbation: changes in circulating eosinophils, basophils and their progenitors. Clin Exp Allergy 1990; 20: 661-668.
17. Dworski R, Fitzgerald GA, Oates JA, Sheller JR: Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953-959.
18. Laviolette M, Malmstrom K, Lu S, et al: Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160: 1862-1868.
19. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB: Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158: 1213-1220.
20. Wickremasinghe RG, Khan MA, Hoffbrand AV: Do leukotrienes play a role in the regulation of proliferation of normal and leukemic hemopoietic cells? Prostaglandins Leukot Essent Fatty Acids 1993; 48: 123-126.